Abstract
Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.
| Original language | English |
|---|---|
| Pages (from-to) | 669-672 |
| Number of pages | 4 |
| Journal | Tumori |
| Volume | 84 |
| Issue number | 6 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Chemotherapy
- Cisplatin
- Epirubicin
- High-dose chemotherapy
- NSCLC
ASJC Scopus subject areas
- Cancer Research
Cite this
Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. / Clerici, M.; De Marinis, F.; Piazza, E.; Frontini, L.; Tucci, E.; Barni, S.; Bretti, S.; Luporini, G.; Intini, C.
In: Tumori, Vol. 84, No. 6, 1998, p. 669-672.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer
AU - Clerici, M.
AU - De Marinis, F.
AU - Piazza, E.
AU - Frontini, L.
AU - Tucci, E.
AU - Barni, S.
AU - Bretti, S.
AU - Luporini, G.
AU - Intini, C.
PY - 1998
Y1 - 1998
N2 - Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.
AB - Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.
KW - Chemotherapy
KW - Cisplatin
KW - Epirubicin
KW - High-dose chemotherapy
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=0032460548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032460548&partnerID=8YFLogxK
M3 - Article
VL - 84
SP - 669
EP - 672
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 6
ER -